Abstract:Infection of mice with Plasmodium berghei ANKA, a murine malaria species, induces remodeling of cerebral endothelial cells, a process which primes the endothelium for the recruitment of inflammatory cells and infected red blood cells to the cerebral microvasculature. Vascular pathology also leads to neuroinflammation, involving the activation of glial cells and abnormal expression of tau proteins in neurons, leading to cognitive dysfunction. Passive immunization to pathological tau with an anti‐PHF‐1 monoclonal antibody mitigates microglial activation and malaria‐induced endotheliopathy, ultimately resulting in the preservation of cognitive function. iR, infected red blood cell; JP, junctional protein; RBC, red blood cell; P, platelet; PHF‐1, paired helical filament 1. Cerebral malaria (CM), a potentially fatal encephalopathy caused primarily by infection with Plasmodium falciparum, results in long‐term adverse neuro‐psychiatric sequelae. Neural cell injury contributes to the neurological deficits observed in CM. Abnormal regulation of tau, an axonal protein pathologically associated with the formation of neurofibrillary lesions in neurodegenerative diseases, has been linked to inflammation and cerebral microvascular compromise and has been reported in human and experimental CM (ECM). Immunotherapy with a monoclonal antibody to pathological tau (PHF‐1 mAB) in experimental models of neurodegenerative diseases has been reported to mitigate cognitive decline. We investigated whether immunotherapy with PHF‐1 mAB prevented cerebral endotheliopathy, neural cell injury, and neuroinflammation during ECM. Using C57BL/6 mice infected with either Plasmodium berghei ANKA (PbA), which causes ECM, Plasmodium berghei NK65 (PbN), which causes severe malaria, but not ECM, or uninfected mice (Un), we demonstrated that when compared to PbN infection or uninfected mice, PbA infection resulted in significant memory impairment at 6 days post‐infection, in association with abnormal tau phosphorylation at Ser202/Thr205 (pSer202/Thr205) and Ser396–404 (pSer396–404) in mouse brains. ECM also resulted in significantly higher expression of inflammatory markers, in microvascular congestion, and glial cell activation. Treatment with PHF‐1 mAB prevented PbA‐induced cognitive impairment and was associated with significantly less vascular congestion, neuroinflammation, and neural cell activation in mice with ECM. These findings suggest that abnormal regulation of tau protein contributes to cerebral vasculopathy and is critical in the pathogenesis of neural cell injury during CM. Tau‐targeted therapies may ameliorate the neural cell damage and subsequent neurocognitive impairment that occur during disease.

Human ApoE2 Protects Mice Against Plasmodium Berghei ANKA Experimental Cerebral Malaria.

Absence of apolipoprotein E protects mice from cerebral malaria

Experimental Cerebral Malaria Alters Blood Lipid Levels during Pathogenesis

ApoE: A new piece to the severe malaria puzzle

Testing the impact of a single nucleotide polymorphism in a Plasmodium berghei ApiAP2 transcription factor on experimental cerebral malaria in mice

Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria

Ag-dependent Engagement of CD8+ T Cells with H-2Kb on Brain Endothelium Required for CD8+ T Cell entry and Cerebral Manifestation of Malaria

Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria

Conditional ablation of H-2Kb and H-2Db on discrete APC subsets modulate outcomes in experimental cerebral malaria

Attenuated T Cell Responses Are Associated With the Blockade of Cerebral Malaria Development by YOP1-Deficient Plasmodium berghei ANKA

Genetic analysis of cerebral malaria in the mouse model infected with Plasmodium berghei

IL-33-Mediated Protection against Experimental Cerebral Malaria Is Linked to Induction of Type 2 Innate Lymphoid Cells, M2 Macrophages and Regulatory T Cells

The CTLA-4 and PD-1/PD-L1 Inhibitory Pathways Independently Regulate Host Resistance to Plasmodium-induced Acute Immune Pathology

Mouse NOD/Shi and NSY/Hos strains infected with Plasmodium berghei ANKA are models for experimental cerebral malaria

Minocycline prevents cerebral malaria, confers neuroprotection and increases survivability of mice during Plasmodium berghei ANKA infection

Plasmodium berghei ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient C57BL/6 mice

Infection-Induced Resistance to Experimental Cerebral Malaria Is Dependent Upon Secreted Antibody-Mediated Inhibition of Pathogenic CD8+ T Cell Responses

Endothelin-1 Mediates Brain Microvascular Dysfunction Leading to Long-Term Cognitive Impairment in a Model of Experimental Cerebral Malaria

Targeting the CD146/Galectin-9 axis protects the integrity of the blood–brain barrier in experimental cerebral malaria

EphA2 contributes to disruption of the blood-brain barrier in cerebral malaria

Heme oxygenase-1 affords protection against noncerebral forms of severe malaria